PTPN21 Plays a Role in Occurrence and Relapse of Acute Lymphoblastic Leukemia By Promoting the Proliferation of Acute Lymphoblastic Leukemic Cells Via Activating MAPK Signal Pathways
Authors: Zhu Ni , Wang Huafang , Xiao Haowen , Tie Ruxiu , Huang He 
Published: October 2019

PTPN21 Plays a Role in Occurrence and Relapse of Acute Lymphoblastic Leukemia by Promoting the Proliferation of Acute Lymphoblastic Leukemic Cells via Activating MAPK Signal Pathways

Accumulating evidences have uncovered the relevance of overexpression in protein tyrosine phosphatases (PTPs) to hematologic malignancies. We analyzed 21 acute lymphoblastic leukemia (ALL) patients and 17 nonmalignant patients as control group in a pilot study. Mononuclear cells were separated from bone marrow samples of these patients via bone marrow aspiration. By real-time fluorescence quantitative PCR, we analyzed the mRNA expression of PTPN21 (tyrosine-protein phosphatase non-receptor type 21), a member of protein tyrosine phosphatases. The mRNA expression of PTPN21 in ALL group was higher than that in control group (10.86¡À2.266 vs. 6.112¡À0.8385, P£¾0.05, Figure 1A), although without significant differences. We divided 21 ALL patients into two groups: new diagnosis or relapse (61.9%, group A) and remission after chemotherapy or HSCT (38.1%, group B). The mRNA expression of PTPN21 in group A was significantly higher than that in control group (15.17¡À3.091 vs. 6.112¡À0.8385, P£¼0.01, Figure 1B) and also higher than that in group B (15.17¡À3.091 vs. 3.845¡À0.731, P£¼0.05, Figure 1B). There was no significant difference between group B and control group (3.845¡À0.731 vs. 6.112¡À0.8385, P£¾0.05, Figure 1B). These data implied that the overexpression of PTPN21 may relate to the occurrence and relapse of ALL.

In order to define the specific mechanisms, we overexpressed PTPN21 in three ALL cell lines by lentiviral transfection, including Jurkat, NALM-6 and Reh cells. We assessed cell cycles by flow cytometry after cells were serum-deprived overnight and stimulated with EGF (epidermal growth factor) for 30 min. We found that cells in G0 phase dramatically decreased and cells in S/G2/M phases dramatically increased after overexpression of PTPN21 (Figure 2). We also detected apoptosis by flow cytometry and found no significant differences between overexpression group and control group. These data demonstrated that overexpression of PTPN21 promoted the proliferation of ALL cells, however didn`t affect the apoptosis of ALL cells.

Next we attempted to figure out the mechanisms that PTPN21 promoted proliferation of ALL cells. We discovered the promotion of dephosphorylation of SRC residue Y527 by western blot analysis, which could stimulate SRC activity. The direct combination of PTPN21 and SRC was demonstrated by immunoprecipitation. The downstream MAPK pathways were also activated by phosphorylation. To be specific, JNK and ERK pathways were activated in Jurkat cells while P38 and ERK pathways were activated in NALM-6 cells. In addition, JNK, P38 and ERK pathways were all activated in Reh cells. In conclusion, our study revealed that PTPN21 may play a role in the occurrence and relapse of ALL by promoting the proliferation of ALL cells via activating SRC and downstream MAPK signal pathways.

Disclosures

No relevant conflicts of interest to declare.